Syndeio Biosciences, Inc
8 clinical trials · Sponsor
◉ Watch Syndeio Biosciences, Inc
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (NCT07115329) | Syndeio Biosciences, Inc | 2026-01-05 |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (NCT06547489) | Syndeio Biosciences, Inc | 2025-02-03 |
| Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers (NCT05597241) | Syndeio Biosciences, Inc | 2022-10-15 |
| Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers (NCT04618263) | Syndeio Biosciences, Inc | 2020-10-26 |
| Zelquistinel in the Treatment of Adults With Major Depressive Disorder (NCT03726658) | Syndeio Biosciences, Inc | 2018-11-08 |
Track Syndeio Biosciences, Inc automatically
Every clearance here is in the API, with alerts when new ones post.